1. aTyr Pharma, Inc. (NASDAQ:ATYR)
1-Year Share Price Performance: ~226%
2-Year Share Price Performance: ~47%
Average Price Target Upside: 455.56%
aTyr Pharma, Inc. (NASDAQ:ATYR) focuses on developing therapies targeting unique immune pathways. Its main drug candidate, efzofitimod, aims to treat pulmonary sarcoidosis and other interstitial lung diseases (ILDs) and is currently in advanced clinical trials. The company is also working on ATYR0101, a preclinical candidate for fibrosis(thickening or scarring of connective tissue in the body), and ATYR0750 for liver disorders.
Its primary candidate, Efzofitimod is an innovative biologic immunomodulator being developed to treat ILD. Derived from tRNA synthetase, efzofitimod works by targeting neuropilin-2 on myeloid cells to control inflammation without suppressing the immune system, potentially slowing fibrosis.
aTyr Pharma, Inc. (NASDAQ:ATYR) recently shared its third-quarter 2024 updates, including progress on key clinical trials for its lead candidate, efzofitimod. The company has completed patient enrollment for the Phase 3 EFZO-FIT study, which evaluates efzofitimod for pulmonary sarcoidosis, and expects preliminary results by Q3 2025.
As of the third quarter, the company held $68.9 million in cash, equivalents, restricted cash, and investments. After the quarter ended, the company raised an additional $19.4 million from an at-the-market offering with Jefferies LLC, before deducting related expenses.
The company expects these funds to support its operations until it files a Biologics License Application (BLA) for efzofitimod in pulmonary sarcoidosis. Research and development expenses for Q3 2024 were $14.8 million, driven largely by clinical trials, manufacturing for efzofitimod, and other research activities. General and administrative expenses totaled $3.3 million for the same period.
On November 8, TipRanks reported that H.C. Wainwright analyst Joseph Pantginis reaffirmed a Buy rating on aTyr (NASDAQ:ATYR), setting a $35 price target. Pantginis highlighted the company’s solid financial footing, ending Q3 2024 with $68.9 million in cash, anticipated to reach $87 million after recent ATM proceeds, which secures funding past the expected Phase 3 trial data release and BLA filing.
The ongoing Phase 3 EFZO-FIT trial for efzofitimod in pulmonary sarcoidosis is pivotal for the company, as there are no FDA-approved treatments for this condition affecting many in the U.S. Early trial enrollment completion also suggests strong interest and significant potential in the upcoming data.
While we acknowledge the potential of aTyr Pharma, Inc. (NASDAQ:ATYR) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than ATYR but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.
Disclosure. None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and investors. Please subscribe to our daily free newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
